tyrosinase/gp100/mart-1 peptides
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2001 (NCT00028431)
Timeline
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tyrosinase/gp100/mart-1 peptides
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00084656 | Phase 2 | May 1, 2004 | Bristol-Myers Squibb, National Cancer Institute (NCI) |
| NCT00028431 | Phase 1 | Aug 1, 2001 | University of Southern California |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 1 | 1 | 1 | 2004 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2004 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 2001 |
3 organizations
Page 1 / 1